ChiCTR2500102738 版本V1.0 版本创建时间2025/05/19 17:09:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500102738 

最近更新日期:

Date of Last Refreshed on:

2025-05-19 17:09:31 

注册时间:

Date of Registration:

2025-05-19 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

驱动压滴定的个体化呼气末正压对食管癌根治术氧合及术后肺部并发症的影响

Public title:

The effect of individualized positive end expiratory pressure titrated by driving pressure on oxygenation and postoperative pulmonary complications in radical resection of esophageal cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

驱动压滴定的个体化呼气末正压对食管癌根治术氧合及术后肺部并发症的影响

Scientific title:

The effect of individualized positive end expiratory pressure titrated by driving pressure on oxygenation and postoperative pulmonary complications in radical resection of esophageal cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘冉 

研究负责人:

刘海林 

Applicant:

Ran Liu 

Study leader:

Hailin Liu 

申请注册联系人电话:

Applicant telephone:

+86 132 1855 3700

研究负责人电话:

Study leader's
telephone:

+86 138 5234 6816

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lr33718@163.com

研究负责人电子邮件:

Study leader's E-mail:

Liuhailin_1971@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省淮安市淮阴区黄河西路1号

研究负责人通讯地址:

江苏省淮安市淮阴区黄河西路1号

Applicant address:

1 Huanghe West Road, Huaiyin District, Huai 'an City, Jiangsu Province

Study leader's address:

1 Huanghe West Road, Huaiyin District, Huai 'an City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学附属淮安第一医院

Applicant's institution:

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

研究负责人所在单位:

南京医科大学附属淮安第一医院

Affiliation of the Leader:

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2023-089-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

淮安市第一人民医院伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First People's Hospital of Huai'an City

伦理委员会批准日期:

Date of approved by ethic committee:

2023-06-12 00:00:00

伦理委员会联系人:

李浩

Contact Name of the ethic committee:

Hao Li

伦理委员会联系地址:

江苏省淮安市淮阴区黄河西路1号

Contact Address of the ethic committee:

1 Huanghe West Road, Huaiyin District, Huai 'an City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 517 8493 6880

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学附属淮安第一医院

Primary sponsor:

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

研究实施负责(组长)单位地址:

江苏省淮安市淮阴区黄河西路1号

Primary sponsor's address:

1 Huanghe West Road, Huaiyin District, Huai 'an City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu Province

City:

单位(医院):

南京医科大学附属淮安第一医院

具体地址:

江苏省淮安市淮阴区黄河西路1号

Institution
hospital:

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

Address:

1 Huanghe West Road, Huaiyin District, Huai 'an City, Jiangsu Province

经费或物资来源:

正常医保报销范围

Source(s) of funding:

Normal insurance coverage

研究疾病:

食管癌  

Target disease:

esophageal cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究的目的是获得驱动压滴定的个体化呼气末正压与术中氧合改善以及术后肺部并发症的相关性,从而指导肺保护策略的实施,降低食管癌术后肺部并发症的发生率,改善患者预后。  

Objectives of Study:

Th study intens to obtain the correlation between individualized positive end expiratory pressuretitrated by driving pressure and intraoperative oxygenation improvement as well as postoperative pulmonary complications, in order to guide the implementation of lung protection strategies, reduce the incidence of postoperative pulmonary complications in esophageal cancer and improve patient prognosis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、年龄18-75岁;2、身体质量指数(BMI)=18.5~25kg/m^2;3、美国麻醉医师协会分级(American society of anesthesiologists,ASA)Ⅰ~Ⅲ级;4、术中单肺通气时间>1h;5、经医院伦理委员会批准,同意签署书面同意书参与此项研究者

Inclusion criteria

1.Age 18-75 years old;2.Body Mass Index(BMI)=18.5~25kg/m^2;3.American society of anesthesiologists(ASA) Grades Ⅰ~Ⅲ;4.The time of one-lung ventilation>1h;5.With the approval of the hospital ethics committee, they agree to sign a written consent to participate in the study;

排除标准:

1、合并严重心血管疾病或严重肝肾功能不全患者;2、既往严重并发症发生史包括肺部感染、胸腔积液、肺不张、呼吸衰竭、心源性肺水肿;3、呼气末正压应用禁忌(张力性气胸,肺大疱,严重气压伤,低血容量性休克,支气管胸膜瘘,高颅内压);4、术中大出血(大于500ml);5、血流动力学不稳定

Exclusion criteria:

1.patients with severe cardiovascular disease or severe hepatic and renal insufficiency; 2.Previous severe complications history including pulmonary infection, pleural effusion, atelectasis, respiratory failure, and cardiogenic pulmonary edema;3.The contraindications of the application of positive end expiratory pressure(tension pneumothorax, pulmonary bullae, severe barotrauma, hypovolemic shock, bronchopleural fistula, high intracranial pressure);4.hemorrhea(>500ml);5.hemodynamic instability

研究实施时间:

Study execute time:

From 2023-06-09 00:00:00 To 2024-06-09 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-12 00:00:00 To 2024-03-20 00:00:00

干预措施:

Interventions:

组别:

T组

样本量:

20

Group:

GroupT

Sample size:

干预措施:

在侧卧位手术期间使用驱动压滴定的个体化呼气末正压,在平卧位手术期间使用固定的5cmH2O呼气末正压

干预措施代码:

Intervention:

Individualized positive end-expiratory pressure titrated by driving pressure was used during surgery in the lateral position and a fixed 5cmH2O positive end-expiratory pressure was used during surgery in the supine position

Intervention code:

组别:

L组

样本量:

20

Group:

GroupL

Sample size:

干预措施:

在平卧位手术期间使用驱动压滴定的个体化呼气末正压,在侧卧位手术期间使用固定的5cmH2O呼气末正压

干预措施代码:

Intervention:

Individualized positive end-expiratory pressure titrated by driving pressure was used during surgery in the supine position and a fixed 5cmH2O positive end-expiratory pressure was used during surgery in the lateral position

Intervention code:

组别:

I组

样本量:

20

Group:

GroupI

Sample size:

干预措施:

手术全程使用个体化呼气末正压

干预措施代码:

Intervention:

Individualized positive end-expiratory pressure was used throughout the procedure

Intervention code:

组别:

P组

样本量:

20

Group:

GroupP

Sample size:

干预措施:

手术全程使用固定的5cmH2O呼气末正压

干预措施代码:

Intervention:

A fixed positive end-expiratory pressure of 5cmH2O was used throughout the procedure

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu Province

City:

单位(医院):

南京医科大学附属淮安第一医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

氧分压

指标类型:

主要指标

Outcome:

Partial pressure of oxygen

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后肺部并发症

指标类型:

次要指标

Outcome:

postoperative pulmonary complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧合指数

指标类型:

主要指标

Outcome:

Oxygenation index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

驱动压

指标类型:

次要指标

Outcome:

driving pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

顺应性

指标类型:

次要指标

Outcome:

compliance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

气道阻力

指标类型:

次要指标

Outcome:

airway resistance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

潮气量

指标类型:

次要指标

Outcome:

Tidal volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

气道峰压

指标类型:

次要指标

Outcome:

Peak airway pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平台压

指标类型:

次要指标

Outcome:

Plateau pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼气末正压

指标类型:

次要指标

Outcome:

Positive end-expiratory pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

酸碱度

指标类型:

次要指标

Outcome:

Ph value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

二氧化碳分压

指标类型:

次要指标

Outcome:

Carbon dioxide partial pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺泡无效腔

指标类型:

次要指标

Outcome:

Alveolar void space

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再次插管情况

指标类型:

次要指标

Outcome:

The situation of reintubation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后第一天氧饱和度

指标类型:

次要指标

Outcome:

Oxygen saturation on the first postoperative day

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

主要负责人通过统计学软件随机分为四组

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients was randomly divided into four groups through statistical software by the director.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

采用单盲法,在本研究中,研究实施者知道研究对象的分组情况,但是研究对象不知道自己所处分组情况。

Blinding:

Using the single-blind method, in this study, the study subjects knew the grouping status, but the study subjects did not know their disciplined group.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan IPD (http://www.medresman.org.cn) .试验结束六个月时间内上传

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan IPD (http://www.medresman.org.cn) .Uploaded within six months of the end of the trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表及电子数据采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collected by Case Record Form and Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-05-19 17:09:31